Overview

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Dexlansoprazole
Esomeprazole
Lansoprazole